We recently performed a translational study to evaluate the potential role of IGF-1R expression on circulating tumor cells (CTCs) of patients enrolled in the MYME trial, which compares first-line CT with first-line CT plus metformin in HER2-negative, metastatic BC patients without diabetes. This evidence concerns the gene IGF1R and breast cancer.